All posts by: Michael Zand

About Michael Zand

Protagen, German Cancer Center Collaborate on Immunotherapy Biomarkers – GenomeWeb

Continue reading

2017-01-17 NEWS

Protagen, German Cancer Center Collaborate on Immunotherapy Biomarkers
GenomeWeb
NEW YORK (GenomeWeb) – Protagen said today that it is collaborating with the German National Center for Tumor Diseases (NCT) Heidelberg to identify biomarkers for predicting response to immunotherapy in melanoma patients. The work will use …

and more »

Continue reading

2017-01-17 NEWS

Local doctor first to offer stem cell procedure
Hometownlife.com
“It is very gratifying to be able to help people of all ages be prepared for future advances in medical science and I am honored to have been selected to be the first in my profession to be trained on stem cell collection,” Schenden said. “This is
LUNA-STEM™ Automated Fluorescence Cell Counter from Logos BiosystemsNews-Medical.net
Stem Cell Therapies Market Key Trends in terms of value Till 2020Satellite PR News (press release)
Stem Cell Therapy Global Market Analysis Research Report 2017-2021NewsMaker (press release)
Medgadget (blog)
all 10 news articles »
Continue reading

2017-01-17 NEWS

The Promise of Tumor Mutational Burden for Cancer Immunotherapy
Genetic Engineering & Biotechnology News
One way to do this is with biomarkers and, for cancer immunotherapy, PD-L1 protein expression is one of the most thoroughly studied. But even from the beginning, it was clear that developing biomarkers for checkpoint inhibitor immunotherapies would be …

Continue reading

2017-01-17 NEWS

Scientific American

1967: Gene Therapy Might Cure Many Illnesses; 1867: The Grandeur of Public Architecture
Scientific American
“Some biologists have wondered if it might someday be possible to alter the genetic material of a human being, for example, to supply a deleted gene and thereby remedy some metabolic deficiency. How would one introduce the desired genetic information?

and more »

Continue reading

2017-01-17 NEWS

In Case You Missed It: The First CRISPR Clinical Trial, A New Shield for Chernobyl—and More!
Scientific American
The first clinical trial to employ cells edited by the genetic tool CRISPR/Cas9 is now under way in China. Three more are scheduled to begin next month. In all four, humans are injected with modified immune cells that researchers hope will fight